Pharmacology/Pharmaceutical Industry
Viewpoint – Regulatory decision-making on COVID-19 vaccines during a public health emergency
1 Sep, 2020 | 06:08h | UTCRegulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency – JAMA
Viewpoint – Emergency use authorizations during the COVID-19 pandemic: Lessons from hydroxychloroquine for vaccine authorization and approval
1 Sep, 2020 | 06:09h | UTC
#ESCCongress – [Abstract Only] Randomized trial: Colchicine in patients with chronic coronary disease
1 Sep, 2020 | 06:04h | UTCColchicine in Patients with Chronic Coronary Disease – New England Journal of Medicine
Commentaries: LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease – TCTMD AND Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease 2 – LoDoCo2 – American College of Cardiology
Commentary on Twitter
Patients with chronic coronary disease were randomized to daily colchicine or placebo. Incidence of the composite endpoint of cardiovascular death, spontaneous MI, ischemic stroke, or ischemia-driven coronary revascularization was significantly lower with colchicine. #ESCCongress
— NEJM (@NEJM) August 31, 2020
Perspective: COVID-19 vaccine trials should seek worthwhile efficacy
31 Aug, 2020 | 01:45h | UTCCOVID-19 vaccine trials should seek worthwhile efficacy – The Lancet
Commentary: Covid vaccine rush could make pandemic worse, say scientists – The Guardian
Commentary on Twitter
"Although efficacy far greater than 50% would be better, efficacy of about 50% would represent substantial progress"
Philip Krause et al for the @WHO Solidarity Vaccines Trial Expert Group on why #COVID19 vaccine trials should seek worthwhile efficacy https://t.co/2VWas8YU7L pic.twitter.com/RjbeZkeAE0
— The Lancet (@TheLancet) August 28, 2020
#ESCCongress – [Abstract Only] Randomized trial: Cardiovascular and renal outcomes with Empagliflozin in heart failure
31 Aug, 2020 | 01:38h | UTCCommentaries: EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF – TCTMD AND EMPEROR-Reduced meets primary endpoint in heart failure with reduced ejection fraction – European Society of Cardiology AND Empagliflozin Outcome Trial in Patients With Chronic Heart Failure and a Reduced Ejection Fraction – EMPEROR-Reduced – American College of Cardiology
Related study: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction – New England Journal of Medicine
Commentary on Twitter
Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
— NEJM (@NEJM) August 29, 2020
#ESCCongress – [Abstract Only] Randomized trial: aspirin with or without clopidogrel after transcatheter aortic-valve implantation
31 Aug, 2020 | 01:33h | UTCCommentaries: Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic-Valve Implantation – POPular TAVI (antiplatelet therapy) – American College of Cardiology AND Go With Aspirin Alone After TAVR When Anticoagulation Isn’t Needed: POPular TAVI – TCTMD
Commentary on Twitter
#ESCCongress #popular_TAVI
Aspirin vs Asp+Clop following #TAVR Aspirin alone:
➡️decrease in bleeding by 40%
➡️No increase in ischemic events
➡️ RRR 26% for net benefit@aayshacader @AnastasiaSMihai @mirvatalasnag @sbrugaletta @Ortega_Paz @willsuh76 @SVRaoMD @DrAsifQasim @iamritu pic.twitter.com/CvUdYgw5mG— Mamas A. Mamas (@mmamas1973) August 30, 2020
#ESCCongress – [Abstract Only] SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
31 Aug, 2020 | 01:36h | UTC
#ESCCongress – [Abstract Only] Randomized trial: Low-dose edoxaban in very elderly patients with atrial fibrillation
31 Aug, 2020 | 01:32h | UTCCommentaries: Edoxaban Low-Dose for Elder Care Atrial Fibrillation – ELDERCARE-AF – American College of Cardiology AND ELDERCARE-AF: Edoxaban Superior to Placebo in Preventing Stroke, Systemic Embolism in Elderly Japanese AFib Patients – American College of Cardiology
Commentary on Twitter
Elderly patients with AF who were not candidates for standard doses of oral anticoagulants because of a high risk of bleeding were assigned to receive 15 mg of edoxaban or placebo once daily. Edoxaban was superior to placebo in preventing stroke or systemic embolism. #ESCCongress
— NEJM (@NEJM) August 30, 2020
#ESCCongress – Randomized trial: Colchicine not beneficial for patients with acute coronary syndrome
31 Aug, 2020 | 01:26h | UTCCommentaries: Colchicine to Improve Cardiovascular Outcomes in ACS Patients – COPS – Circulation
Commentary on Twitter
Colchicine in Patients with Acute Coronary Syndrome: The Australian COPS RCT vs COLCOT RCT #ESCCongress 🔴 seemingly opposite results, dose start time patients? @almucastro01 @ValleAlfonso @JoseJuanatey @Dr_Manito @secardiologia @varrarte @sociedadSEEN 🤔🩺https://t.co/uagW2HRGPt pic.twitter.com/SQoVsbzG0m
— Oscar Moreno # (@moreno_perez_o) August 30, 2020
#ESCCongress – Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
31 Aug, 2020 | 01:23h | UTCCommentary: Colchicine Cardiovascular Outcomes Trial – COLCOT – American College of Cardiology
Commentary on Twitter
#ESCCongress #COLCOT Study looking at TTI colchicine to assess if timing impacted outcomes
❤️ACS treatment with colchicine 🆚 placebo: 23%⤵️ in events
❤️Randomized w/in 30days postMI
🔺TTI (Time to Treat Initiation) 0-3d 🆚 4-7d 🆚 8-30d
🔺0-3 days had better outcomes pic.twitter.com/iQAkts1BG9— Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 (@DrMarthaGulati) August 30, 2020
#ESCCongress – [Abstract Only] Randomized trial: Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy
31 Aug, 2020 | 01:21h | UTCCommentary: EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class – TCTMD
Commentary on Twitter
Latebreaking now at #ESCCongress—Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial https://t.co/JcJnGI0VVt pic.twitter.com/Xmf98Bcoir
— The Lancet (@TheLancet) August 29, 2020
Perspective: We’ve got a Coronavirus vaccine update for you
28 Aug, 2020 | 08:43h | UTCWe’ve Got a Coronavirus Vaccine Update for You – Self
Guideline synopsis: Ulcerative colitis in adults
28 Aug, 2020 | 08:38h | UTCUlcerative Colitis in Adults – JAMA
Podcast: Update on Ulcerative Colitis—2020
Original Guideline: AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis – Gastroenterology
Too many COVID-19 patients get unneeded ‘just in case’ antibiotics
27 Aug, 2020 | 10:00h | UTCToo many COVID-19 patients get unneeded ‘just in case’ antibiotics – University of Michigan
Pandemic debate: Should doctors recommend treatments and vaccines when full data are not publicly available?
27 Aug, 2020 | 09:49h | UTC
Commentary on Twitter
In normal circumstances, insisting on full data transparency and limiting decision making to published data alone is rightly paramount. But what about during a pandemic? https://t.co/pUvM9PK47s
— The BMJ (@bmj_latest) August 26, 2020
BCG vaccination in infancy does not protect against COVID-19. Evidence from a natural experiment in Sweden
26 Aug, 2020 | 04:12h | UTC
Systematic review: Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19
26 Aug, 2020 | 04:05h | UTCCommentaries: Expert reaction to study looking at blood pressure medicines and COVID-19 – Science Media Centre AND Coronavirus Treatment: Blood Pressure Medicines May Reduce COVID-19 Severity, Deaths: Study – International Business Times
Observational study: Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis
26 Aug, 2020 | 03:57h | UTC
Randomized trial: Vitamin D Supplementation does not prevent severe asthma exacerbations in children with asthma and low vitamin D levels
26 Aug, 2020 | 03:52h | UTCEffect of Vitamin D3 Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels: The VDKA Randomized Clinical Trial – JAMA (free for a limited period)
Commentary: Compared to placebo, vitamin D has no benefit for severe asthma attacks, study finds – University of Pittsburgh School of Medicine AND Don’t count on vitamin D to ease childhood asthma – MedicalXpress
Commentary on Twitter
In this RCT, #vitaminD3 supplementation did not improve the time to a severe asthma exacerbation vs placebo in children with persistent asthma and low #vitaminD levels https://t.co/VfYXUrhyT7
— JAMA (@JAMA_current) August 25, 2020
Vaccines targeting SARS-CoV-2 tested in humans
25 Aug, 2020 | 03:56h | UTCVaccines targeting SARS-CoV-2 tested in humans – Nature Medicine
Commentary on Twitter
No #SARSCoV2 vaccine has yet to be shown to be effective or safe.
Effective = it prevents infections.
Safe = it doesn't engender serious adverse effects.https://t.co/dsyk8m6pEx@NatureMedicine
Please keep this in mind now that @US_FDA's @SteveFDA has lost all credibility pic.twitter.com/OgQIpDPv6R— Eric Topol (@EricTopol) August 24, 2020
Randomized trial: Mifepristone and misoprostol vs. misoprostol alone for the management of missed miscarriage
26 Aug, 2020 | 03:54h | UTCInvited commentary: Medical management of miscarriage with mifepristone – The Lancet
WHO: 172 countries and multiple candidate vaccines engaged in COVID-19 vaccine Global Access Facility
25 Aug, 2020 | 03:48h | UTC
Commentary on Twitter
Urgent, broadscale commitment & investment from countries is🔑to achieve the goal of COVAX to bring the pandemic under control by accelerating the development & manufacture of #COVID19 vaccines, & to guarantee fair & equitable access for all countries🌐
👉https://t.co/CPNzyTjsLz pic.twitter.com/jBupCY7dur
— World Health Organization (WHO) (@WHO) August 24, 2020
The unequal scramble for coronavirus vaccines — by the numbers
25 Aug, 2020 | 03:47h | UTCThe unequal scramble for coronavirus vaccines — by the numbers – Nature
Meta-analysis: Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients
25 Aug, 2020 | 03:40h | UTC
The neuroleptic malignant syndrome—a systematic case series analysis focusing on therapy regimes and outcome
25 Aug, 2020 | 03:37h | UTCCommentary: Treating Neuroleptic Malignant Syndrome: A Case Series – NEJM Journal Watch